BioAge Labs

BioAge Labs is a clinical-stage biopharmaceutical company focused on developing therapies that target the biological mechanisms of aging to treat metabolic diseases. The company operates at the intersection of aging biology and metabolic health, using proprietary multi-omics data to identify molecular pathways that influence both processes.

The lead program, azelaprag, is an oral therapy designed to work alongside incretin-based weight loss drugs. This combination approach aims to enhance weight reduction while improving body composition metrics beyond what single-agent therapies achieve. Azelaprag targets specific aging-related pathways that influence metabolism and fat distribution.

BioAge employs a human-first discovery platform that analyzes large-scale datasets linking genetic and molecular markers to health outcomes in aging populations. This methodology identifies therapeutic targets validated in human cohorts rather than animal models alone. The platform has generated a pipeline of candidates addressing metabolic aging through mechanisms distinct from conventional diabetes and obesity treatments.

The company research focuses on pathways where aging biology intersects with metabolic dysfunction, including mitochondrial health, cellular senescence and inflammatory signaling. These targets represent approaches to metabolic disease that account for age-related physiological changes affecting treatment response and disease progression.